Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Hold” by Analysts

Posted by on Jul 23rd, 2026

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have earned a consensus rating of “Hold” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $5.54.

Several research firms have recently commented on ESPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. Cantor Fitzgerald lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Jefferies Financial Group cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Piper Sandler downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Finally, Citizens Jmp lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st.

Get Our Latest Report on ESPR

Insiders Place Their Bets

In other Esperion Therapeutics news, insider Benjamin Looker sold 11,824 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total value of $37,245.60. Following the transaction, the insider owned 667,524 shares in the company, valued at approximately $2,102,700.60. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Benjamin Halladay sold 10,773 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $33,934.95. Following the transaction, the chief financial officer directly owned 702,829 shares of the company’s stock, valued at approximately $2,213,911.35. This trade represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. R Squared Ltd boosted its position in Esperion Therapeutics by 23.5% during the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 2,890 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Esperion Therapeutics by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 3,614 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Esperion Therapeutics by 49.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC raised its position in shares of Esperion Therapeutics by 9.4% in the 4th quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Esperion Therapeutics by 18.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 4,422 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

ESPR stock opened at $3.18 on Thursday. Esperion Therapeutics has a 52 week low of $1.10 and a 52 week high of $4.18. The firm’s fifty day moving average is $3.15 and its 200 day moving average is $3.00. The firm has a market cap of $819.45 million, a P/E ratio of -53.00 and a beta of 1.07.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.The business had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

Featured Stories

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.